INFECTIONS OF THE IMMUNOCOMPROMISED HOST: Edited by José G. MontoyaTreatment of cryptococcosis in non-HIV immunocompromised patientsHenao-Martínez, Andrés F.a; Chastain, Daniel B.b; Franco-Paredes, Carlosa,cAuthor Information aDepartment of Medicine, Division of Infectious Diseases, University of Colorado Denver, Aurora, Colorado bDepartment of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Albany, Georgia, USA cHospital Infantil de México, Federico Gómez, México City, México Correspondence to Andrés F. Henao-Martínez, MD, University of Colorado Denver 12700 E. 19th Avenue, Mail Stop B168, Aurora, CO 80045,. USA. Tel: +1 720 848 0820; fax: +1 720 848 0191; e-mail: [email protected] Current Opinion in Infectious Diseases: August 2018 - Volume 31 - Issue 4 - p 278-285 doi: 10.1097/QCO.0000000000000458 Buy Metrics Abstract Purpose of review Cryptococcosis has become a common opportunistic infection among non-HIV immunocompromised hosts. Recent reports have shown the incidence of Cryptococcosis among HIV-negative immunocompromised patients reaches close to half of the overall cases reported in the USA. Management of this infection in this population carries unique challenges. We aim to review relevant and recent research findings to develop treatment recommendations for this type of population. Recent findings Most of the recommendations for the management of non-HIV immunocompromised host are extrapolated from HIV studies. Cryptococcosis among non-HIV patients is common but often overlooked. Some clinical factors, when present, may increase the risk of Cryptococcosis among HIV-negative patients and appropriate screening and assessment for the disease is necessary. Treating clinicians should consider a longer duration of induction with Amphotericin B depending on the type of host, immunocompromised state, antifungal response and presence of neurological complications. Baseline fluconazole resistance can reach up to 12%, which is an important consideration for cryptococcal meningitis relapses or suboptimal responses to therapy. Summary Cryptococcus spp. conveys a high disease burden among immunocompromised hosts. Clinicians must consider numerous variables and factors in a dynamic way to offer the best possible treatment and to monitor their response to therapy. Due to the high cost and associated toxicities, we still need new affordable therapies and studies among non-HIV immunocompromised patients. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.